Bristol Myers Squibb - News
网页2024年9月10日 — Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
Bristol Myers Squibb - Bristol Myers Squibb Completes Acquisition …
网页2024年3月18日 — Bristol Myers Squibb will provide an update to its financial outlook when it reports first quarter 2024 results on April 25, 2024. Advisors. Gordon Dyal & Co. and Citi are serving as financial advisors to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.
Bristol Myers Squibb - Bristol Myers Squibb Adds Premier ...
网页2023年12月26日 — PRINCETON, N.J. & SAN DIEGO--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash ...
Bristol Myers Squibb Announces Leadership Transition Plan
网页2023年4月26日 — NEW YORK-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that Giovanni Caforio, MD, Chairman of the Board and Chief Executive Officer, has decided to retire as Chief Executive Officer, effective November 1, 2023.
Bristol Myers Squibb - U.S. Food and Drug Administration …
网页2022年9月9日 — Bristol Myers Squibb’s Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque psoriasis in nearly 10 years
Bristol Myers Squibb - U.S. FDA Approves Bristol Myers Squibb’s …
网页2022年6月24日 — Bristol Myers Squibb: Creating a Better Future for People with Cancer. Bristol Myers Squibb is inspired by a single vision—transforming patients’ lives through science. The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility.
Bristol Myers Squibb - Bristol Myers Squibb to Acquire Turning …
网页2022年6月3日 — Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company. Acquisition Brings Repotrectinib, a Potential Best-in-Class, Next-Generation ROS1/NTRK Inhibitor with Differentiated Duration of Response for Patients with ROS1-positive First-Line Non-Small Cell Lung Cancer; Expected to …
Bristol Myers Squibb Strengthens and Diversifies Oncology …
网页2023年10月8日 — Through this acquisition, Bristol Myers Squibb will add KRAZATI, an important lung cancer medicine, to its commercial portfolio. The company gains access to several promising clinical assets that complement its oncology pipeline and are strong candidates for single agent development and combination strategies.
Bristol Myers Squibb - Bristol Myers Squibb and 2seventy bio …
网页2024年2月5日 — PRINCETON, N.J., & CAMBRIDGE, Mass.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced that a notice was published in the Federal Register that the U.S. Food and Drug Administration (FDA) will convene a virtual meeting of the Oncologic Drugs Advisory Committee (ODAC) on March 15, 2024, to ...
Bristol Myers Squibb - Bristol Myers Squibb Announces Pivotal …
网页KRYSTAL-12 is an open-label, multicenter, randomized Phase 3 study evaluating KRAZATI compared to standard-of-care chemotherapy alone, in patients with KRAS G12C -mutated non-small cell lung cancer. The primary endpoint of the study is PFS as assessed by BICR.